Sunday, April 23

Welcome and Keynote Address
7:00 p.m.-8:30 p.m.

Introduction and Welcome
Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas
Jennifer Rubin Grandis, University of California, San Francisco, California
J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, California
Quynh-Thu Le, Stanford Cancer Institute, Palo Alto, California

Historical perspective
Waun Ki Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas

Opening Keynote Lecture
5:45 p.m.-7:00 p.m.

Title to be announced
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, Texas

Opening Reception
7:45 p.m.-8:30 p.m.

Monday, April 24

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 1: Detection and Prevention
8:00 a.m.-9:15 a.m.
Session Chair: William N. William, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas

Detection of tumor DNA in the saliva and plasma of patients with HNSCC
Nishant Agrawal, University of Chicago Pritzker School of Medicine, Chicago, Illinois

Oral cancer prevention
Joseph A. Califano, University of California, San Diego, La Jolla, California

Immunoprevention of oral cancers
William N. William, Jr., The University of Texas MD Anderson Cancer Center, Houston, Texas

Break
9:15 a.m.-9:35 a.m.

Plenary Session 2: Novel Targets and Biomarkers in Head and Neck Cancer
9:35 a.m.-10:50 a.m.
Session Chair: Eduardo Mendez, University of Washington, Seattle, Washington

As of February 15, 2017
Identification of Wee-1 as a potential target for treating head and neck cancer and clinical evaluation of a Wee-1 inhibitor
Eduardo Mendez

New targeted therapies in AML
Jolanta E. Grembecka, University of Michigan, Ann Arbor, Michigan

PI3 Kinase and the regulation of head and neck cancer stem cells
Antonio Jimeno, University of Colorado Cancer Center, Aurora, Colorado

Personalizing HNSCC treatment based on TP53 mutational status
Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas

Short talks from proffered abstracts
10:50 am-11:50 am
Session Chair: Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas

Lunch on Own
11:50 a.m.-1:45 p.m.

Plenary Session 3: Cancer Genomics and Signatures of Mutational Processes in Human Cancer
1:45 pm-3:25 pm
Session Chair: Jennifer Rubin Grandis, University of California, San Francisco, California

Comprehensive genomic characterization of head and neck squamous cell carcinomas
Jennifer Rubin Grandis

Integrated omics analyses identify prognostic biomarkers of oral cavity squamous cell carcinoma in Taiwan
Kai-Ping Chang, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Interactions between the genome and immune microenvironment in head and neck cancer
Luc G.T. Morris, Memorial Sloan Kettering Cancer Center, New York, New York

Functional genomic screens in head and neck cancer
Mitchell J. Frederick, Baylor College of Medicine, Houston, Texas

Poster Session / Reception
3:30 p.m.-6:00 p.m.

Evening off / Dinner on Own
6:00 p.m.-

Tuesday, April 25

Continental Breakfast
7:00 a.m.-8:00 a.m.

Plenary Session 4: Breakthroughs in Imaging Head and Neck Cancers
Session Chair: Quyen T. Nguyen, University of California, San Diego, California
8:00 a.m.-9:40 a.m.
Real-time near-infrared fluorescence tracer imaging in sentinel node biopsy for oral cavity cancer patients and identification of the unknown primary
Christian Von Buchwald, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Optimizing head and neck cancer treatment outcomes with MRI
Stephen Y. Lai, The University of Texas MD Anderson Cancer Center, Houston, Texas

Molecular navigation for cancer diagnosis and surgery: Imaging tumors and nerves
Quyen T. Nguyen

Midtreatment metabolic imaging as a biomarker of treatment response
Quynh-Thu Le, Stanford Cancer Institute, Palo Alto, California

Break
9:40 a.m.-10:00 a.m.

Plenary Session 5: Clinical Management / Outcomes / Survivorship/ Disparities
10:00 a.m.-11:40 a.m.
Session Chair: Harry Quon, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Treatment de-intensification strategies for head and neck cancer
Barbara A. Burtness, Smilow Cancer Hospital/Yale Cancer Center, New Haven, Connecticut

Optimizing oncologic outcomes and swallowing function with radiotherapy
Harry Quon

Grading dysphagia in head and neck cancer: Clinical and imaging methods
Katherine A. Hutcheson, The University of Texas MD Anderson Cancer Center, Houston, Texas

Oncologic and quality-of-life outcomes for patients with oropharyngeal cancer treated with robotic surgery or definitive chemoradiotherapy
Umamaheswar Duvvuri, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Lunch on own
11:40 a.m.-1:00 p.m.

Plenary Session 6: Immune Checkpoint Blockade in Cancer Therapies / Immunobiology / Targeting the Immune System
1:00 pm-2:40 pm
Session Chair: Robert L. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania

Immunocompetent models of head and neck cancer
Ravindra Uppaluri, Dana-Farber Cancer Institute, Boston, Massachusetts

Overcoming MDSC mediated suppression of tumor immunity
Clint T. Allen, National Institutes of Health, Bethesda, Maryland

HPV vaccine based immunotherapy
Robert L. Ferris

As of February 15, 2017
Biomarkers and checkpoint inhibition in HNSCC
Ezra E.W. Cohen, UCSD Moores Cancer Center, La Jolla, California

Plenary Session 7: Viral Cancers HPV/EBV
2:20 pm-3:35 pm
Session Chair: Maura L. Gillison, Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Differences in oral HPV natural history by sex, and potential impact of HPV vaccination on HPV-OPC
Gypsyamber D’Souza, Johns Hopkins University, Baltimore, MD

HPV infection, genomic instability, and outcome in OPSCC
Maura L. Gillison

Current management of NPC
Anthony T. Chan, Chinese University of Hong Kong, Hong Kong, SAR

Summary and Closing Remarks
3:35 p.m.-4:00 p.m.

J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, California
Jeffrey N. Myers, The University of Texas MD Anderson Cancer Center, Houston, Texas

As of February 15, 2017